NervGen Pharma (DE:9UA)
FRANKFURT:9UA
9UA Stock Chart & Stats
€3.50
-€0.04(-2.08%)
At close: 4:00 PM EST
€3.50
-€0.04(-2.08%)
Day’s Range― - ―
52-Week Range€1.53 - €5.00
Previous CloseN/A
Volume2.00
Average Volume (3M)33.00
Market Cap
€130.60M
Enterprise Value€396.61M
Total Cash (Recent Filing)€11.40M
Total Debt (Recent Filing)€33.23K
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding80,930,870
10 Day Avg. Volume50
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)82.04
Price to Sales (P/S)0.00
P/FCF Ratio-12.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.21Price Target Upside191.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low recorded debt (roughly $33K TTM) materially reduces near-term creditor pressure and bankruptcy risk. For a cash-burning biotech, minimal leverage preserves optionality with lenders and allows management to prioritize equity or strategic financings over costly debt, a durable balance-sheet advantage.
Focused Clinical Pipeline (NVG-291)A concentrated R&D program centered on NVG-291 focuses resources on a single differentiated nerve-regeneration candidate. This focused platform can accelerate decision cycles, align trial design and regulatory engagement, and if clinical success occurs, deliver high upside from a clear addressable therapeutic niche.
Regulatory/data Catalysts And Financing FlexibilityRecent CONNECT SCI data, active FDA pathway discussions and a $10M private placement plus a Form F-10 filing represent structural progress: supportive clinical/regulatory engagement and explicit financing runway improve ability to continue development and pursue U.S. listing or follow-on raises under a regulated framework.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow (~-$16.8M TTM) creates an enduring need for outside capital. This structural cash consumption increases dilution risk, pressures management to secure financing on market-dependent terms, and can constrain long-term program continuity if capital markets tighten.
Pre-revenue With Widening LossesZero revenue and widening net losses (around -$25.8M TTM) limit internal funding sources and lengthen the path to self-sufficiency. For a clinical-stage biotech, persistent increasing losses reduce margin of safety and raise dependency on successful trials or partnerships to materially alter the company's financial trajectory.
Negative Equity And Shrinking AssetsMaterial deterioration to negative shareholder equity and a drop in total assets (from ~$23.9M to ~$13.1M) weaken the balance sheet's capacity to absorb shocks. This structural deterioration can raise financing costs, limit strategic options, and increase the likelihood of dilutive raises or asset sales to fund operations.
NervGen Pharma News
9UA FAQ
What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was €1.53 and its highest was €5.00 in the past 12 months.
What is NervGen Pharma’s market cap?
NervGen Pharma’s market cap is €130.60M.
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is Aug 12, 2026 which is in 65 days.
How were NervGen Pharma’s earnings last quarter?
Currently, no data Available
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate is -0.06.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 80,930,870 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in DE:9UA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NervGen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.21 (191.62% Upside)
€10.21 (191.62% Upside)
Insider Transactions
Bought Shares
Worth €1.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.02%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
35.21%
Trailing 12-Months
Company Description
NervGen Pharma
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
9UA Stock 12 Month Forecast
Average Price Target
€10.21
▲(191.62% Upside)
Technical Analysis
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―
Options Prices
Currently, No data available
---